Its sale to Allergan was called off at the last minute. One year later, a biotech co-founded by Henri Termeer finds a new buyer

Submitted by admin on October 1, 2020 - 10:01am

Source:

Endpoints

News Tags:

Lysosomal Therapeutics

Allergan

R&D

M&A

Henri Termeer

Bial

Headline:

Its sale to Allergan was called off at the last minute. One year later, a biotech co-founded by Henri Termeer finds a new buyer

snippet:

Lysosomal Therapeutics went into JP Morgan 2017 with a sale all but sealed. With $100 million upfront and a $48 million cash infusion to execute on the R&D plan, Allergan lined up an exclusive option to buy the Cambridge, MA-based biotech once the Phase I safety and proof-of-concept data for its lead drug are in.

Search form

You are here

Its sale to Allergan was called off at the last minute. One year later, a biotech co-founded by Henri Termeer finds a new buyer

Its sale to Allergan was called off at the last minute. One year later, a biotech co-founded by Henri Termeer finds a new buyer